mCPP: an undesired addition to the ecstasy market.

Autor: Bossong MG; Drug Information and Monitoring System (DIMS), Trimbos Institute for Mental Health and Addiction, Utrecht, The Netherlands. M.Bossong@umcutrecht.nl, Brunt TM, Van Dijk JP, Rigter SM, Hoek J, Goldschmidt HM, Niesink RJ
Jazyk: angličtina
Zdroj: Journal of psychopharmacology (Oxford, England) [J Psychopharmacol] 2010 Sep; Vol. 24 (9), pp. 1395-401. Date of Electronic Publication: 2009 Mar 20.
DOI: 10.1177/0269881109102541
Abstrakt: A new ecstasy-like substance, meta-chlorophenylpiperazine (mCPP), has been detected in street drugs in the Netherlands. Theoretically, mCPP possesses the potential to become a non-neurotoxic alternative for methylenedioxymethamphetamine (MDMA), the regular psychoactive substance of ecstasy. Since its introduction on the Dutch market of synthetic drugs, the percentage of mCPP-containing tablets has increased, including both tablets that contain only mCPP and tablets containing a combination of mCPP and MDMA. These tablets occur in many different colours, shapes and sizes and with various logos, making it impossible to distinguish mCPP-containing tablets from regular MDMA tablets. In addition, the reports of users concerning the effects of mCPP are predominantly negative. All these aspects together lead to the conclusion that mCPP is an undesired addition to the ecstasy market from the user's perspective.
Databáze: MEDLINE